THDB(SH:600867)2023-05-11 16:00Financial Performance - The net profit attributable to the parent company for 2022 was CNY 1,581,891,736.52, with the parent company achieving a net profit of CNY 1,611,418,685.58 after a 10% statutory surplus reserve allocation of CNY 161,141,868.56[4] - The total distributable profit at the end of 2022 was CNY 3,025,515,327.35, after accounting for the beginning retained earnings of CNY 2,700,547,905.49 and the payment of ordinary share dividends amounting to CNY 1,095,782,446.10[4] - The proposed cash dividend distribution is CNY 2.50 per 10 shares (including tax), totaling CNY 495,919,668.50 (including tax) based on the adjusted share capital[4] - The cash dividend accounted for 74.36% of the net profit attributable to shareholders in the consolidated financial statements for the year[5] - The company’s net profit attributable to ordinary shareholders for the year was 1,581,891,736.52 RMB, with a dividend payout ratio of 62.70%[168] Revenue and Profit Trends - The company's operating revenue for 2022 was ¥2,778,453,059.19, a decrease of 14.98% compared to ¥3,267,897,464.66 in 2021[20] - The net profit attributable to shareholders for 2022 was ¥1,581,891,736.52, an increase of 20.92% from ¥1,308,254,212.79 in 2021[20] - The net cash flow from operating activities decreased by 26.88% to ¥863,094,112.65 in 2022 from ¥1,180,365,738.97 in 2021[20] - The total profit for 2022 was CNY 1,829.52 million, an increase of 19.23% year-on-year[31] Market Position and Product Development - The company’s insulin product sales volume reached 73.76 million units in 2022, a year-on-year increase of 14.92%[34] - The market share of human insulin increased to 40.50%, surpassing Novo Nordisk, making the company the leader in the national market[34] - The company expanded its product portfolio with the approval of Aspart Insulin 30 and Aspart Insulin 50 injections, enhancing treatment options[33] - The company is focusing on expanding its research in endocrine metabolism, with ongoing projects in diabetes and gout treatments[35] Research and Development - The company has developed a comprehensive product line in diabetes treatment, including long-acting, medium-acting, and rapid-acting insulin, as well as GLP-1RA products[66] - The company is advancing its GLP-1 receptor agonist research, with Liraglutide injection expected to receive market approval by the end of 2023[44] - The company has established R&D centers in multiple cities, continuously enhancing its research capabilities and focusing on diabetes and other endocrine diseases[99] - The company reported a significant investment of RMB 4,977.59 million in the development of soluble insulin injections, which accounted for 1.79% of operating income, reflecting a 206.93% increase compared to the previous year[109] Corporate Governance and Compliance - The company has maintained stable leadership with no changes in the board of directors and senior management during the reporting period[137] - The company is committed to developing a management framework that supports long-term growth and addresses challenges related to rapid expansion[125] - The company has implemented management control over subsidiaries, ensuring compliance with relevant laws and regulations[178] - The company has not faced any penalties from securities regulatory authorities in the past three years[144] Environmental Responsibility - The company has actively invested in environmental protection measures, including upgrades to coal-fired boiler emission control systems[183] - The company has transitioned to using natural gas as the primary fuel for its boilers, eliminating the use of coal and reducing air pollution[193] - The company has published its 2022 Social Responsibility Report, available on the Shanghai Stock Exchange website[195] - The company has established an emergency response plan for environmental incidents, which was approved by experts and filed with the local environmental protection bureau in October 2022[188] Employee Management and Incentives - The company is implementing a multi-layered incentive mechanism to improve employee performance and retention, including performance assessments and stock options[52] - The company has established a training plan to enhance employee skills, including new employee orientation, on-the-job training, and external training programs[162] - The total number of employees at the parent company and major subsidiaries is 3,054, with 3,021 at the parent company and 33 at major subsidiaries[160] - The company emphasizes a reasonable salary policy based on employee qualifications, skills, and work performance, ensuring mutual benefit between labor and management[161] Strategic Initiatives - The company is actively seeking local partners in various regions to strengthen its international market presence and enhance overseas commercialization efforts[49] - The company plans to explore the potential of GLP-1RA drugs in treating obesity and NASH, with the global obesity drug market projected to reach $54 billion by 2030 and the NASH drug market expected to reach $32.2 billion[56] - The company is committed to expanding its international presence by registering insulin and GLP-1RA products in overseas markets and seeking partnerships with large foreign pharmaceutical companies[123] - The company aims to provide integrated solutions for diabetes management, including a complete insulin supply system and high-quality blood glucose monitoring systems[120]